Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1623 1658 1693 1699
This examiner grants 60% of resolved cases
Benjamin Michael Brandsen serves in Tech Center 1600 and Art Unit 1623. The examiner has a record of 113 resolved cases. These cases result in an allowance rate of 60.2%, which indicates the frequency of grants for applications reaching a final disposition. The median days to allowance is 1264, providing a benchmark for the expected duration of the prosecution cycle. Practitioners can use the 60.2% allowance rate to assess the likelihood of a successful outcome when an application is assigned to this examiner.
The data shows an interview lift of 18.6%. This lift suggests that interviews are an effective tool for communication, potentially improving the 60.2% allowance rate. The 1264-day median to allowance reflects the pace of the examination process in Art Unit 1623. Practitioners should consider these metrics when advising clients on the timeline and probability of grant. The consistency seen across 113 resolved cases offers a predictable environment for patent prosecution.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17772940 | AZAPODOPHYLLOTOXIN DERIVATIVES AND METHODS OF TREATING LYMPHOMA AND KIDNEY CANCER | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 17904907 | COMPOSITION AND METHOD TO PREPARE LONG-ACTING INJECTABLE SUSPENSION CONTAINING MULTIPLE CANCER DRUGS | Non-Final OA | University of Washington |
| 18305840 | WATER DISPERSABLE FILM-FORMING COMPOSITION | Final Rejection | AMOREPACIFIC CORPORATION |
| 18001655 | THERAPEUTIC TREATMENT USING PROTEIN KINASE C (PKC) INHIBITORS AND CYTOTOXIC AGENTS | Non-Final OA | Cambridge Enterprise Limited |
| 17250952 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | Non-Final OA | ALNYLAM PHARMACEUTICALS, INC. |
| 18572316 | 4-ETHYNYL-3-HYDROXY-TETRAHYDROFURANYL-ADENINE PHOSPHORAMIDATES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Non-Final OA | ROME THERAPEUTICS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy